Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice., Xue Chen, Ting Zhang, Hongyang Liu, Yaru Hao, Guoyang Liao, Xuemei Xu, 2018
Lipidated L2 epitope repeats fused with a single-chain antibody fragment targeting human Fc gamma RI elicited cross-neutralizing antibodies against a broad spectrum of human papillomavirus types., Ting Zhang, Hongyang Liu, Xue Chen, Zhirong Wang, Shuo Wang, Chunfeng Qu, Jingzhi Zhang, Xuemei Xu, 2016
A Vaccine of L2 Epitope Repeats Fused with a Modified IgG1 Fc Induced Broadly Cross-Neutralizing Antibodies and Protective Immunities against Divergent Human Papillomavirus., Xue Chen, Hongyang Liu, Ting Zhang, Yanchun Liu, Xixiu Xie, Zhirong Wang, Xuemei Xu, 2014
HSP70 and modified HPV 16 E7 fusion gene without the addition of a signal peptide gene sequence as a candidate therapeutic tumor vaccine., Jinbao Zong, Changyuan Wang, Qingyong Wang, Qinglin Peng, Yufei Xu, Xixiu Xie, Xuemei Xu, 2013
The immune complex CTA1-DD/IgG adjuvant specifically targets connective tissue mast cells through FcγRIIIA and augments anti-HPV immunity after nasal immunization., Yu Fang, Ting Zhang, Linnea Lidell, Xuemei Xu, Nils Lycke and Zou Xiang, 2013
Human papillomavirus type 58 L1 virus-like particles purified by two-step chromatography elicit high levels of long-lasting neutralizing antibodies., Xixiu Xie, Yanchun Liu, Ting Zhang, Yanying Xu, Qifeng Bao, Xue Chen, Hongyang Liu, Xuemei Xu, 2012
Comparison of Two High-Throughput Assays for Quantification of Adenovirus Type 5 Neutralizing Antibodies in a Population of Donors in China., Qiang Liu, Jianhui Nie, Weijin Huang, Shufang Meng, Baozhu Yuan, Dongying Gao, Xuemei Xu, Youchun Wang, 2012
Trivalent Human Papillomavirus (HPV) VLP vaccine covering HPV type 58 can elicit high level of humoral immunity but also induce interference among component types., Ting Zhang, Yufei Xu, Liang Qiao, Youchun Wang, Xueling Wu, Dongsheng Fan, Qinglin Peng, Xuemei Xu, 2010
Deglycosylation of HIV-1 AE Gp140 enhance the capacity to elicit neutralizing antibodies agains the heterologous HIV-1 clade., Congyou Zhang, Yanmin Wan, Shi jinhong, Xuemei Xu, Jianqing Xu, 2010
Human HSP70 and modified HPV16 E7 fusion DNA vaccine induces enhanced specific CD8+T cell responses and anti-tumor effects., Jinbao Zong, Qinglin Peng, Qingyong Wang, Ting Zhang, Dongsheng Fan, Xuemei Xu, 2009
Human papillomaviruses and cervical vaccines: To decode 2008 Nobel Prize in physiology or medicine., Xuemei Xu, 2008
Enhancement of vaccine potency by fusing modified LTK63 into human papillomavirus type 16 chimeric virus-like particles., Yufei Xu, Hongtao Zhang, Xuemei Xu, 2008
The type-specific and cross-reactive neutralizing antibodies induce by human papillomavirus type 31 L1/L2 Virus-like Particles., Yufei Xu, Qingyong Wang, Xuemei Xu, 2007
Encapsidating artificial human papillomavirus-16 mE7 protein in human papillomavirus-6b L1/L2 virus like particles., Yufei Xu, Qingyong Wang, Hongtao Zhang, Yehua Han, Xuemei Xu, 2007
The efficacy a DNA vaccine containing inserted and replicated regions of the E7 gene for treatment of HPV 16 induced tumors., Joeli A. Brinkman, Xuemei Xu, W. Martin Kast, 2007
Area of Focus
Gene Engineering | Nk Cells | T Cells | Anticancer | Targeted Therapy | Immunotherapy | Cancer Treatment | Mitochondrial Apoptosis | Drug Resistance | Immunotherapy Efficacy
